Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $161,851.90 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard Prins sold 7,973 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total transaction of $161,851.90. Following the completion of the transaction, the director owned 29,625 shares in the company, valued at $601,387.50. This represents a 21.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $20.91 on Friday. The firm has a 50-day moving average of $19.83 and a two-hundred day moving average of $21.19. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71. The stock has a market cap of $889.51 million, a P/E ratio of 12.37, a PEG ratio of 4.26 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a 1-year low of $16.65 and a 1-year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%.The business had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. On average, research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Rice Hall James & Associates LLC boosted its holdings in Amphastar Pharmaceuticals by 54.6% in the first quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company’s stock worth $3,670,000 after purchasing an additional 66,172 shares during the period. Denali Advisors LLC raised its holdings in shares of Amphastar Pharmaceuticals by 56.9% during the fourth quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock worth $5,671,000 after purchasing an additional 76,765 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 47.1% during the first quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock worth $5,122,000 after purchasing an additional 83,739 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Amphastar Pharmaceuticals by 12.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after buying an additional 228,262 shares during the last quarter. Finally, Bridge City Capital LLC lifted its position in shares of Amphastar Pharmaceuticals by 72.8% in the 4th quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock worth $6,306,000 after buying an additional 99,227 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AMPH shares. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Wells Fargo & Company raised their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Six equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Reduce” and a consensus target price of $22.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.